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Highlights 
 First report of parental mosaicism in RYR1-related Central Core Disease (CCD). 
 Expands the genotypic spectrum of RYR1-related disorders. 
 Important implications for genetic counselling. 
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ABSTRACT (150 words) 
 
Myopathies due to mutations in the skeletal muscle ryanodine receptor (RYR1) gene are 
amongst the most common non-dystrophic neuromuscular disorders and have been associated 
with both dominant and recessive inheritance. Several cases with apparently de novo 
dominant inheritance have been reported.  
Here we report two siblings with features of Central Core Disease (CCD) born to unaffected 
parents. Genetic testing revealed a heterozygous dominant RYR1 c.14582G>A (p. 
Arg4861His) mutation previously identified in other CCD pedigrees. The variant was absent 
in blood from the asymptomatic mother but detected at low but variable levels in blood- and 
saliva-derived DNA from the unaffected father, suggesting that this mutation has arisen as a 
paternal post-zygotic de novo event.  
These findings suggest that parental mosaicism should be considered in RYR1-related 
myopathies, and may provide one possible explanation for the marked intergenerational 
variability seen in some RYR1 pedigrees. 
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INTRODUCTION 
 
Mutations in RYR1 encoding the type 1 ryanodine receptor (RyR1), the principal 
sarcoplasmic reticulum calcium release channel with a crucial role in excitation-contraction 
(EC) coupling, are the most common cause of non-dystrophic neuromuscular disorders. 
RYR1-related disorders comprise an extremely wide clinical spectrum, ranging from early-
onset congenital myopathies of variable severity to induced and episodic phenotypes – 
malignant hyperthermia (MH) [1], (exertional) rhabdomyolysis (ERM) [2] and periodic 
paralysis (PP) [3] – in otherwise healthy individuals. Whilst MH and Central Core Disease 
(CCD), the two disorders originally attributed to disturbed RyR1 function in the 1990s [4], 
are mainly associated with dominant inheritance of genetic variants localizing to 3 mutational 
hotspots within the large RYR1 gene, recessive mutations distributed throughout the entire 
RYR1 coding sequence have,  more recently, been implicated in subgroups of various 
congenital myopathies [5], including Multi-minicore Disease (MmD) [6], Centronuclear 
Myopathy (CNM) [7] and Congenital Fibre Type Disproportion (CFTD) [8]. Apparent de 
novo dominant mutations have also been recognized, often associated with particularly severe 
manifestations [9]. 
The genetics of RYR1-related myopathies have become increasingly complex: Reflective of 
the high mutation rate of the large RYR1 gene, digeny for mutations in RYR1 and other 
neuromuscular genes [10, 11] as well as multiple clearly pathogenic RYR1 variants running 
independently in the same pedigree [12, 13] have now been repeatedly reported. There is 
often considerable intra- and interfamilial variability in families with RYR1-related 
myopathies that often remains unaccounted for [5].    
Here we report CCD in two siblings due to a heterozygous dominant RYR1 mutation 
inherited from an asymptomatic father with somatic mosaicism.     
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CASE REPORT 
 
Patients 
Patient 1: The index case is a 6-year-old girl who presented with bilateral hip dysplasia from 
birth and subsequent motor developmental delay.  
She was delivered from a cephalic position 12 days post term following a normal pregnancy. 
There were no feeding or respiratory problems. Clinically suspected congenital dislocation of 
the hips was confirmed on hip ultrasound and treated with open hip reduction and subsequent 
hip spica cast.  
She sat unsupported at 7 months and started crawling at 14 months. Following removal of the 
hip spica cast at 18 months, she made further slow developmental progress. She was cruising 
around the furniture at 24 months, took her first independent steps at around 28 months and 
walked unaided from around three years of age. She is currently able to walk up to 200 
metres at a time but tires very easily and falls frequently.  
On a recent examination she had mildly myopathic features but a full range of eye 
movements. She had a positive Gowers’ sign and an exaggerated lordosis. There was 
moderate weakness pronounced axially and in the hip girdle.  
An ultrasound of the right thigh showed marked involvement of the quadriceps, with almost 
complete loss of the femoral bone echo but relative preservation of the rectus femoris, as 
typically seen in RYR1-related myopathies.
 
Previous investigations included normal CK 
levels (at 65 IU/L) and a normal array CGH. EMG/NCS suggested a myopathic process.  
Reviewing the family history, she was the first child of a healthy non-consanguineous 
Caucasian couple. There was a history of not further defined hip problems in two female 
cousins of the maternal grandfather. On the paternal side of the family, the paternal 
grandmother had an undefined problem with her spine that required bracing.   
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Patient 2: This currently almost 3-year-old boy is the younger brother of Patient 1. He was 
delivered by normal vaginal delivery at term following an uneventful pregnancy. Apart from 
gastroesophageal reflux there were no problems in the neonatal period.  
He sat unsupported from 7 months, bottom shuffled from 11 months and crawled around the 
same time, but did not walk independently until18 months of age. At the age of two years and 
five months, he can crawl up stairs but is still unable to run and falls very frequently.  
On a recent examination, there were no overtly myopathic features and the range of eye 
movements were full. He had a positive Gowers’ sign. There was truncal and proximal 
weakness more pronounced in the hip girdle.  
Muscle ultrasound of the right thigh showed features like those in his sister, with marked 
involvement of the vasti and with relative sparing of the rectus femoris. 
 
Muscle biopsy 
A muscle biopsy was obtained from the quadriceps in the older sister at the age of 4 years 4 
months and was compatible with a histopathological diagnosis of CCD (Figure 1). There was 
increased variability in fibre size, increased endomysial connective tissue and scattered 
internal and central nuclei. There was type 1 fibre uniformity as suggested on oxidative and 
immunohistochemical stains with antibodies to the slow myosin isoform. There were also 
few very small “pin prick” fibres staining positive with antibodies to the fetal myosin 
isoform. On NADH-TR and SDH stains there were well-defined, centrally located cores in 
most fibres. Cores ran for a significant extent along the fibre axis on longitudinal sections. 
Cores were to a lesser extent visible on H&E and PAS stains, with a rim of increased 
glycogen staining on the latter.   
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Genetic testing  
Genetic testing was performed through a custom-made next generation sequencing (NGS) 
panel covering 36 genes implicated in various congenital myopathies. This revealed a 
heterozygous RYR1 c. 14582G>A (p. Arg4861His) sequence variant in the index case, 
confirmed on direct Sanger sequencing of DNA. The c.14582G>A (p. Arg4861His) variant 
occurs in a highly conserved amino acid, is absent from the ExAC data set 
(http://exac.broadinstitute.org/) and has been previously reported in several individuals with 
CCD and other RYR1-related myopathies [5]. NGS in the index case, patient 1, also identified 
a  previously unreported heterozygous NEB c.17897C>T (p. Pro5966Leu) variant of 
uncertain significance. Further cosegregation studies in the family by direct Sanger 
sequencing using the same primers confirmed the heterozygous RYR1 c.14582G>A (p. 
Arg4861His) variant in the similarly affected brother. The RYR1 variant was absent from the 
asymptomatic mother but detected at low but variable levels in blood- and saliva-derived 
DNA from the unaffected father (Figure 2), suggesting that this mutation has arisen as a 
paternal post-zygotic de novo event. The unaffected mother was found to carry the NEB 
c.17897C>T (p. Pro5966Leu) variant of uncertain significance which is unlikely to be 
contributory to the phenotype in the affected siblings. 
 
DISCUSSION 
 
Mosaicism, the common occurrence of mutant and wild-type cells in the same tissue, is the 
result of a postzygotic mutation; depending on the developmental stage where it has 
occurred, this may affect germline cells, somatic cells, or both [14]. Depending on the tissues 
affected, as in our case mosaicism may be detected on Sanger sequencing of DNA extracted 
from lymphocytes or other cells routinely used for genetic testing, but may escape detection 
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if only the germline is affected, certain tissues are spared or mutant expression levels are too 
low to be detected on routine testing.  Although Sanger sequencing is not a quantitative 
assay, as in this family it is often possible to conclude mosaicism based on the ratio between 
the 2 nucleotide traces. 
Considering important implications for both genetic counselling and prognosis, parental 
mosaicism is an important concern in apparently sporadically affected children born to 
asymptomatic parents without unequivocal mutational evidence for recessive inheritance. 
The phenotypical expression in the mosaic carrier and the associated recurrence risk in their 
offspring are highly variable, depending on the tissue affected, mutant to wild-type ratio and 
tissue-dependent tolerance of the mutant allele.      
Parental mosaicism has been reported in a wide range of dominantly inherited human 
diseases, including subgroups of congenital myopathies due to dominant mutations in DNM2 
[15] and ACTA1 [16, 17], as well as X-linked recessive myotubular myopathy (XLMTM) 
[18, 19].  Parental mosaicism has also recently been reported in COL6-related myopathies 
[20, 21], accounting at least partially for the often marked variability seen in some families 
affected by these disorders. 
Previously only suggested in one family consisting of a severely affected child and a mildly 
affected mother with the recurrent RYR1 p.Ala4940Thr mutation [22], parental mosaicism 
has also been documented in rare pedigrees with catecholaminergic polymorphic ventricular 
tachycardia (CPVT), a familial and potential fatal arrhythmia due to dominant mutations in 
RYR2, the cardiac ryanodine receptor isoform. In one of these families, maternal somatic 
mosaicism was detected following symptom manifestation in the sibling of a girl considered 
to be sporadically affected [23], in the other maternal somatic mosaicism was identified on a 
more extensive genetic screen of a family with 3 typically affected siblings without a 
preceding family history [24].     
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The finding of parental mosaicism for a heterozygous dominant RYR1 mutation has important 
implications for the approach to RYR1-related myopathies and may potentially explain 
several, currently unaccounted for observations concerning these common neuromuscular 
disorders. Firstly, marked intergenerational variability has been recognized in RYR1 
pedigrees [5], and, in addition to the presence of multiple mutations or other genetic 
modifiers, may at least be partially accounted for by somatic mosaicism in some family 
members, corresponding to recent findings in dominantly inherited COL6-related myopathies 
[20, 21]. Along similar lines, somatic mosaicism in the parental generation may also account 
for the peculiar observation of apparent “anticipation” between two generations in some CCD 
pedigrees reported in the pre-molecular era [25]. Secondly, somatic mosaicism may at least in 
some instances also explain the discordance between genotype and phenotype, in particular a 
discrepancy between results of genetic testing and the in vitro contracture test (IVCT), that 
has been reported in some families with RYR1-related MH [26]. Lastly, although some RYR1 
mutations may have genuinely occurred de novo, apparent de novo inheritance of a RYR1-
related myopathy ought to prompt a careful search for somatic mosaicism which may easily 
be missed if the parental mutation is not expressed in blood lymphocytes.     
In conclusion, this report emphasizes parental mosaicism as a relevant mechanism in RYR1-
related myopathies that ought to be considered and carefully investigated for, bearing in mind 
important implications for counselling. Parental mosaicism may also provide one possible 
explanation for the intergenerational variability observed in some RYR1 pedigrees, and for 
cases with presumably recessive RYR1-related myopathies in whom only one RYR1 
mutation has been identified.  
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Figure 1 
Muscle biopsy from the right quadriceps in the index case at 4 years 4 months of age. 
Sections stained with haematoxylin and eosin (A) show mild myopathic fibre size variation, 
with a dispersed population of small fibres measuring 10 μm or less (arrows, A). Oxidative 
stains NADH-TR (B) and COX (C) show well-demarcated large, central or eccentric cores 
devoid of mitochondria, seen as lack of oxidative activity in a majority of fibre and 
accompanied by uniformity of staining. Some cores display an enhanced rim of oxidative 
staining. Immunostaining for slow myosin (D) and fast myosin (E) confirms the 
overwhelming slow fibre predominance and retained immunoreactivity for slow myosin 
within cores suggesting that most of them are structured cores. Fetal myosin (arrows, F) 
labels a dispersed population of mostly very small (“pin prick”) fibres measuring less than 5 
μm. Many of these very small fibres are also immunoreactive for fast myosin (E). Scale bar: 
A-F: 100 μm 
 
Figure 2 
(A) Pedigree of the family reported in this paper. Black symbols indicate the Central Core 
Disease (CCD) phenotype, +/- indicates heterozygous mutation carriers, -/- indicates the non-
mutation carriers and “mos” indicates the mosaicism. (B) Sequencing analyisis of blood-
derived DNA demonstrating heterozygous carrier state of the c. 14582G>A p. (Arg4861His) 
RYR1 mutation in the two siblings with CCD (II-1 and II-2, arrows) and somatic mosaicism 
in the unaffected father (I-1, circle), reflected in a small green peak not present in the 
unaffected mother (I-2) and a normal control (C). Somatic mosaicism was also identified in 
saliva-derived paternal DNA (data not shown).  
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